Evaluation of a new mucolytic agent. (Sabath, Sasahara, Burleson)

L. D. Sabath, A. A. Sasahara, V. A. Burleson

Research output: Contribution to journalArticlepeer-review


A controlled study was performed to determine whether an ascorbic acid-percarbonate-copper sulfate mixture would be of value in treating chronic bronchitis. A secondary purpose was to evaluate some methods of studying mucolytic agents. The drug Gumox (ascoxal) was administered by inbalation to 9 patients, each of whom on a different day, also received isotonic saline solution as control material. The immediate physiologic effect of the drug mixture was not significantly different from that of the aline control, both being associated with comparative improvements in the one second vital capacity (1-sec VC), maximal expiratory flow rate (MEFR) and maximal voluntary ventilation (MVV). However, the delayed effect of the drug, registered 1 day after treatment, showed further improvement in all 3 functions tested, while these values following saline treatment had returned to or toward the starting baseline.
Original languageUndefined/Unknown
Pages (from-to)47-56
Number of pages10
JournalDiseases of the chest
Issue number1
StatePublished - 1966


  • chronic bronchitis
  • controlled study
  • drug mixture
  • forced expiratory volume
  • lung fibrosis
  • lung ventilation
  • patient
  • peak expiratory flow
  • radiation
  • vital capacity
  • ascorbic acid
  • copper sulfate
  • mucolytic agent
  • sodium chloride

Cite this